NCT06548802View on ClinicalTrials.gov

Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Pulmonary Injury After Intracerebral Hemorrhage
Interventions
DRUG

Baricitinib

Baricitinib was given 4mg once daily, with the first dose taken within 24 hours of the appearance of lung injury and continued for 14 days.

Trial Locations (1)

300052

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
collaborator

First Affiliated Hospital of Fujian Medical University

OTHER

lead

Tianjin Medical University General Hospital

OTHER